FOEHR MATTHEW W
SEC CIK 1237556 · EDGAR
BoughtSold
Most active insiders at OABI, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FOEHR MATTHEW W | Pres, CEO, Dir | — | $143.5K |
| 2 | HIGGINS JOHN L | Dir | $107.7K | — |
| 3 | GUSTAFSON KURT A | CFO, Executive VP, Fin | — | $84.7K |
| 4 | Berkman Charles S | CLO | — | $54.9K |
| 5 | Crouse Steven C. | Dir | — | — |
| 6 | Gotwals Philip J | Dir | — | — |
| 7 | Cochran Jennifer R. | Dir | — | — |
| 8 | Bertozzi Carolyn R | Dir | — | — |
| 9 | Love Steven | Dir | — | — |
Transactions 60
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-07 20:26 | 2026-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $0.00 | +36.5K | 4.44M | +0.8% | $0 |
| D | 2026-04-07 20:26 | 2026-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $1.49 | -19.2K | 4.42M | -0.4% | -$28.7K |
| D | 2026-02-18 | 2026-02-18 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | — | +58.3K | 4.43M | +1% | — |
| D | 2026-02-18 | 2026-02-18 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $1.71 | -30.8K | 4.40M | -0.7% | -$52.7K |
| D | 2026-02-17 | 2026-02-16 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $0.00 | +36.5K | 4.40M | +0.8% | $0 |
| D | 2026-02-17 | 2026-02-17 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $1.70 | -20.8K | 4.38M | -0.5% | -$35.3K |
| D | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Dir | A - Grant | $0.00 | +3,150 | 135.2K | +2% | $0 |
| D | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Dir | M - OptEx | $3.33 | +16.0K | 148.0K | +12% | +$53.3K |
| D | 2026-01-05 | 2026-01-02 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Dir | S - Sale+OE | $35.11 | -16.0K | 132.0K | -11% | -$561.8K |
| D | 2025-12-09 | 2025-12-08 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $1.96 | -13.7K | 4.36M | -0.3% | -$26.8K |
| D | 2025-12-09 | 2025-12-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $0.00 | +26.6K | 4.37M | +0.6% | $0 |
| 2025-08-26 | 2025-08-26 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | A - Grant | $1.85 | +540.5K | 4.34M | +14% | +$1000.0K | |
| D | 2025-04-14 | 2025-04-11 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Dir | M - OptEx | $8.00 | +20.8K | 132.0K | +19% | +$166.3K |
| D | 2025-04-07 | 2025-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $0.00 | +36.5K | 3.82M | +1.0% | $0 |
| D | 2025-04-07 | 2025-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $2.00 | -19.4K | 3.80M | -0.5% | -$38.8K |
| DM | 2025-02-19 | 2025-02-15+ | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | — | +63.0K | 3.78M | +2% | — |
| DM | 2025-02-19 | 2025-02-18+ | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $3.67 | -33.5K | 3.78M | -0.9% | -$123.0K |
| 2025-01-22 | 2025-01-21 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale | $3.24 | -41.8K | 3.75M | -1% | -$135.5K | |
| 2025-01-22 | 2025-01-17 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | A - Grant | $0.00 | +77.0K | 3.79M | +2% | $0 | |
| D | 2024-12-10 | 2024-12-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | — | +26.6K | 3.73M | +0.7% | — |
| D | 2024-12-10 | 2024-12-09 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | S - Sale+OE | $4.13 | -13.6K | 3.71M | -0.4% | -$56.3K |
| DM | 2024-11-26 | 2024-11-25 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $3.73 | +99.4K | 3.63M | +3% | +$370.7K |
| DM | 2024-06-27 | 2024-06-27 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $3.73 | +59.7K | 3.56M | +2% | +$222.4K |
| 2024-05-28 | 2024-05-24 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $4.42 | +240.0K | 3.54M | +7% | +$1.06M | |
| A | 2024-04-23 | 2022-11-01 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | A - Grant | — | +1.43M | 3.30M | +77% | — |
| D | 2024-04-09 | 2024-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | — | +36.5K | 3.19M | +1% | — |
| D | 2024-04-09 | 2024-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | F - Tax | $5.31 | -18.5K | 3.17M | -0.6% | -$98.1K |
| DM | 2024-03-29 | 2024-03-27 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | M - OptEx | $3.72 | +243.6K | 3.15M | +8% | +$907.0K |
| 2024-03-25 | 2024-03-22 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $5.19 | +225.0K | 2.91M | +8% | +$1.17M | |
| DM | 2024-02-20 | 2024-02-15 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | M - OptEx | — | +37.3K | 2.68M | +1% | — |
| DM | 2024-02-20 | 2024-02-15 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | F - Tax | $5.54 | -18.9K | 2.67M | -0.7% | -$104.8K |
| D | 2024-01-03 | 2024-01-02 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | F - Tax | $6.25 | -13.2K | 2.67M | -0.5% | -$82.6K |
| D | 2024-01-03 | 2024-01-02 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | M - OptEx | — | +33.2K | 2.68M | +1% | — |
| 2023-12-13 | 2023-12-12 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | P - Purchase | $5.05 | +200.0K | 2.65M | +8% | +$1.01M | |
| D | 2023-12-11 | 2023-12-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | F - Tax | $4.85 | -9,184 | 2.45M | -0.4% | -$44.5K |
| D | 2023-12-11 | 2023-12-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | M - OptEx | — | +26.6K | 2.45M | +1% | — |
| 2023-11-13 | 2023-11-10 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $4.27 | +95.0K | 2.43M | +4% | +$405.6K | |
| 2023-08-15 | 2023-08-14 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $5.48 | +45.0K | 2.33M | +2% | +$246.6K | |
| 2023-06-12 | 2023-06-09 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | P - Purchase | $4.52 | +115.0K | 2.57M | +5% | +$519.8K | |
| 2023-05-15 | 2023-05-12 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | P - Purchase | $3.40 | +440.0K | 2.44M | +22% | +$1.50M | |
| D | 2023-04-11 | 2023-04-07 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | CEO, Dir | A - Grant | $0.00 | +109.4K | 2.00M | +6% | $0 |
| M | 2023-02-17 | 2023-02-15 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | F - Tax | $3.80 | -17.1K | 1.89M | -0.9% | -$64.9K |
| 2023-01-05 | 2023-01-03 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | A - Grant | $0.00 | +79.7K | 1.91M | +4% | $0 | |
| 2022-12-30 | 2022-12-28 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | F - Tax | $3.66 | -11.6K | 1.83M | -0.6% | -$42.5K | |
| 2022-12-14 | 2022-12-12 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $3.77 | +150.0K | 1.84M | +9% | +$565.5K | |
| 2022-12-05 | 2022-12-01 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | F - Tax | $3.35 | -17.3K | 1.69M | -1% | -$57.8K | |
| 2022-12-01 | 2022-11-30 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $3.39 | +300.0K | 1.71M | +21% | +$1.02M | |
| 2022-11-09 | 2022-11-09 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | P - Purchase | $2.76 | +100.0K | 1.41M | +8% | +$276.0K | |
| D | 2022-11-03 | 2022-11-01 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Former Executive Off | D - Sale to Iss | — | -20.3K | 162.2K | -11% | — |
| D | 2022-11-03 | 2022-11-01 | OABI | OmniAb, Inc. | FOEHR MATTHEW W | Pres, CEO, Dir | A - Grant | — | +1.31M | 1.31M | New | — |
| 2022-06-14 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | A - Grant | $0.00 | +9,137 | 182.5K | +5% | $0 | |
| 2022-05-13 | 2022-05-13 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | P - Purchase | $82.76 | +2,500 | 173.4K | +1% | +$206.9K | |
| 2022-05-03 | 2022-05-02 | VKTX | Viking Therapeutics, Inc. | FOEHR MATTHEW W | Dir | P - Purchase | $2.47 | +45.0K | 111.2K | +68% | +$111.2K | |
| M | 2022-02-16 | 2022-02-15 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | F - Tax | $123.68 | -3,546 | 171.9K | -2% | -$438.6K |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | F - Tax | $113.68 | -5,125 | 174.4K | -3% | -$582.6K |
| M | 2022-01-28 | 2022-01-26 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | A - Grant | $0.00 | +13.0K | 179.5K | +8% | $0 |
| DM | 2021-11-12 | 2021-11-11 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | M - OptEx | $28.54 | +12.2K | 177.7K | +7% | +$347.8K |
| D | 2021-11-12 | 2021-11-11 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | S - Sale+OE | $163.02 | -11.2K | 166.5K | -6% | -$1.82M |
| DM | 2021-08-05 | 2021-08-04 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | M - OptEx | $29.23 | +9,982 | 165.5K | +6% | +$291.7K |
| D | 2021-08-05 | 2021-08-04 | LGND | LIGAND PHARMACEUTICALS INC | FOEHR MATTHEW W | Pres, COO | S - Sale+OE | $109.67 | -8,840 | 164.4K | -5% | -$969.5K |
Purchase Sale Sale after option exercise All abbreviations